Milestone Pharmaceuticals announces first European participant enrolled in Revera-301 Phase 3 trial
MIST•Milestone Pharmaceuticals announced that the first European study participant has enrolled in its Revera-301 Phase 3 clinical trial.
MIST•MIST•
